On its current trajectory, Omeros Corporation (NASDAQ: OMER) might be heading into a short squeeze thanks to its high short data. With this in mind, a short squeeze requires a catalyst to help the stock run and OMER stock has no shortage of upcoming catalysts. As we are in the second half of 2023, OMER intends to release trial data regarding 2 treatments this half...
🔸Hello traders, let's review the daily price chart for OMER today. We got strong ongoing
accumulation in range since april 2022. Trading in well defined range and chart looks good.
Range highs set near 5.8 usd and range lows set at 2.50 usd. Premium prices overhead at
7.50 usd and below at 1.80/2.00 usd. Currently trading near range highs, so naturally...
Opportunity for a massive short squeeze. Need volume to confirm a short squeeze is taking place. Stop below today's low.
Short float >20%.
You don't need to know what's going to happen next to make money ~Mark Douglas
Lose like a pro and keep trading, or lose like a novice and quit ~Mark Ritchie
In 2021 Omeros Corporation (OMER) delivered great results, net income was $194.2 million or $3.12 per share VS a net loss of $138.1 million or $2.41 net loss per share in 2020.
On 1/18/2022 Cantor Fitzgerald Lower Price Target for OMER from $34.00 to $20.00.
I think a reversal to the $8.50 resistance is possible.
Looking forward to read your opinion about it.
$OMER - Renko (90 ATR, 90 min)
we use stoch/mfi/rsi together with default settings.
this is a very choppy chart to analyze if you chart it normally.
renko allows us to filter that choppiness.
Stoch oversold, MFI on trigger zone, RSI moving to oversold zone.
we must wait for the price to reverse to neckline before we make entry ( > $12.50 )
also this may be a...
Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19-Associated Acute Respiratory Distress Syndrome
-- All six patients, requiring mechanical ventilation prior to treatment, recovered, survived and were discharged from the hospital
-- Narsoplimab treatment was associated with rapid and sustained improvement across all...
Major downtrends broken after earnings beat.
Possible entry level above resistance $15.05
Target price $17.17
Stop loss $14.30
Company profile
Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications...
Watching for a break above $14.75. nice base consolidation here. Former runner. Ascending wedge pattern. 10, 20 and 50 EMA forming a nice floor for a stop loss. See if it holds $14 or not. No position yet.
Risk: biotechs normally I avoid, but this has a nice pattern. Also on guard for any overall market weakness which will probably negate this as a potential...
